Literature DB >> 12642842

Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris.

Takashi Kakinuma1, Hidehisa Saeki, Yuichiro Tsunemi, Hideki Fujita, Noriko Asano, Hiroshi Mitsui, Yayoi Tada, Motoshi Wakugawa, Takahiro Watanabe, Hideshi Torii, Mayumi Komine, Akihiko Asahina, Koichiro Nakamura, Kunihiko Tamaki.   

Abstract

BACKGROUND: Both atopic dermatitis (AD) and psoriasis vulgaris (PsV) are characterized as chronic and relapsing inflammatory skin diseases associated with various immunologic abnormalities. Cutaneous T cell-attracting chemokine (CTACK; CCL27) is a member of the CC chemokine family and a functional ligand for CC chemokine receptor 10. It is selectively expressed in skin and attracts CC chemokine receptor 10-expressing skin-homing memory T cells. The epidermal keratinocyte is a main source of CTACK, suggesting the involvement of various inflammatory skin diseases.
OBJECTIVE: The purpose of this investigation was to clarify whether CTACK produced by keratinocytes is detected in the sera of patients with AD and PsV and to examine the correlation between the serum CTACK levels and disease activity of patients with AD and PsV.
METHODS: We measured the serum CTACK levels in 50 patients with AD, 30 patients with PsV, and 22 healthy control subjects. We also divided 50 patients with AD into 3 groups (ie, those with mild, moderate, and severe disease) and compared them among 3 categories. Moreover, we compared the serum CTACK levels of patients with AD and PsV with clinical or laboratory data. Immunohistochemical staining of CTACK and IFN-induced protein of 10 kd (IP-10; CXCL10) was performed on the lesional skin of patients with AD and PsV.
RESULTS: The serum CTACK levels in patients with AD and PsV were significantly higher than those in healthy control subjects. The serum CTACK levels in patients with AD significantly correlated with scoring atopic dermatitis (SCORAD) scores, serum soluble IL-2 receptor levels, serum soluble E-selectin levels, serum thymus and activation-regulated chemokine levels, and serum macrophage-derived chemokine levels. Serum CTACK levels in patients with PsV significantly correlated with the serum IP-10 levels but not with the Psoriasis Area and Severity Index score. Immunohistochemical staining showed CTACK was strongly expressed in lesional ke-ratinocytes of patients with AD and PsV, whereas IP-10 was strongly expressed in lesional keratinocytes of patients with PsV and focally in those with AD.
CONCLUSION: These results suggest that CTACK might be one of the important chemokines for the pathogenesis of AD and PsV.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12642842     DOI: 10.1067/mai.2003.114

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  29 in total

Review 1.  CCR10 and its ligands in regulation of epithelial immunity and diseases.

Authors:  Na Xiong; Yaoyao Fu; Shaomin Hu; Mingcan Xia; Jie Yang
Journal:  Protein Cell       Date:  2012-06-08       Impact factor: 14.870

2.  Selective Expression of CCR10 and CXCR3 by Circulating Human Herpes Simplex Virus-Specific CD8 T Cells.

Authors:  Michael T Hensel; Tao Peng; Anqi Cheng; Stephen C De Rosa; Anna Wald; Kerry J Laing; Lichen Jing; Lichun Dong; Amalia S Magaret; David M Koelle
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

Review 3.  CCR6 as a possible therapeutic target in psoriasis.

Authors:  Michael N Hedrick; Anke S Lonsdorf; Sam T Hwang; Joshua M Farber
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

4.  Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.

Authors:  Kimberly A Kraynyak; Michele A Kutzler; Neil J Cisper; Amir S Khan; Ruxandra Draghia-Akli; Niranjan Y Sardesal; Mark G Lewis; Jian Yan; David B Weiner
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

Review 5.  Therapeutic Benefits of Natural Ingredients for Atopic Dermatitis.

Authors:  George Man; Li-Zhi Hu; Peter M Elias; Mao-Qiang Man
Journal:  Chin J Integr Med       Date:  2017-09-01       Impact factor: 1.978

6.  Lesional skin chemokine CTACK/CCL27 expression in mycosis fungoides and disease control by IFN-alpha and PUVA therapy.

Authors:  Gaia Goteri; Serena Rupoli; Anna Campanati; Antonello Costagliola; Simona Sabato; Daniela Stramazzotti; Paola Picardi; Lucia Canafoglia; Stefano Pulini; Giulia Ganzetti; Anna Maria Offidani; Pietro Leoni
Journal:  Am J Transl Res       Date:  2009-01-31       Impact factor: 4.060

Review 7.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Sarah L Chamlin; Steven R Feldman; Jon M Hanifin; Eric L Simpson; Timothy G Berger; James N Bergman; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2013-11-27       Impact factor: 11.527

Review 8.  Role of bacterial pathogens in atopic dermatitis.

Authors:  Yu-Tsan Lin; Chen-Ti Wang; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2007-12       Impact factor: 8.667

9.  Auf1/Hnrnpd-deficient mice develop pruritic inflammatory skin disease.

Authors:  Navid Sadri; Robert J Schneider
Journal:  J Invest Dermatol       Date:  2008-10-02       Impact factor: 8.551

10.  Serum mucosa-associated epithelial chemokine in atopic dermatitis: a specific marker for severity.

Authors:  M H M Ezzat; K Y Shaheen
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.